AGP Executive Report
Last update: 11 hours agoAI in Medicine: Alibaba open-sourced Damo Radar, a vision-language model that flags nearly 150 abdominal conditions from contrast CT scans, aiming to cut missed diagnoses by 10% and speed reads by 30%+—a big step for faster, more consistent imaging support. US–China Pharma Rules: Reuters reports the U.S. is drafting rules that could preserve most licensing deals for Chinese drugs, while tightening national-security guardrails around pathogen/weaponizable biotech. China Biotech Push: China’s MIIT unveiled a 2026-2030 plan targeting 25% of first-in-class drugs to originate in China and growing biotech output to 3.5 trillion yuan by 2030. Medical Tourism: Jiahui Health says inbound medical tourism is surging, citing 1.28 million international patient visits in 2025 and policy/visa facilitation as key drivers. Public Health & Safety: U.S. states and regulators are cracking down on counterfeit GLP-1s tied to Chinese supply chains, while China also drafts guidelines to protect minors online with “minor mode” restrictions. Wellness Market: Elite Asia Group launched an integrative TCM center blending AI with acupuncture/cupping and an “AI Mugwort Robot” for moxibustion.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.